Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FiTNEss trial in transplant-ineligible newly diagnosed multiple myeloma
ISRCTN17973108Phase 3Active, not recruiting
- Sponsor
- University of Leeds
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ixazomib, lenalidomide, dexamethasone and Placebo-COD Research Private Ltd in multiple myeloma (MM) (4 arms), sponsored by University of Leeds. Primary endpoints: Early treatment cessation and Progression-free survival after randomisation 2. Started Aug 2020; status: active, not recruiting.
02
Drugs
ixazomiblenalidomidedexamethasonePlacebo-COD Research Private Ltd
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN17973108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17973108.